Wall Street is positive on TG Therapeutics Inc common stock (TGTX). On average, analysts give TG Therapeutics Inc common stock a Strong Buy rating. The average price target is $28.388, which means analysts expect the stock to climb by 7.65% over the next twelve months.
That average ranking earns TG Therapeutics Inc common stock an Analyst Rating of 45, which is better than 45% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating TGTX a Strong Buy today. Find out what this means to you and get the rest of the rankings on TGTX!
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With TG Therapeutics Inc common stock Stock Today?
TG Therapeutics Inc common stock (TGTX) stock has fallen -0.71% while the S&P 500 is higher by 0.32% as of 12:42 PM on Monday, Jun 5. TGTX is lower by -$0.19 from the previous closing price of $26.56 on volume of 771,372 shares. Over the past year the S&P 500 is higher by 4.24% while TGTX is higher by 567.59%. TGTX lost -$1.23 per share the over the last 12 months.
Click Here to get the full Stock Report for TG Therapeutics Inc common stock stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
